Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 216

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 216
---
 of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ WithumSmith+Brown, PC

We have served as the Company’s auditor since 2025.

Whippany, New Jersey

May 6, 2025

<div align='center'>F-10</div>

IRIS PARENT HOLDING CORP. CONSOLIDATED BALANCE SHEETS

| ​                                                                                                                                          
 ​                                                                                                                                          
 ​                                                                                                                                          
 Assets                                                                                                                                     
 Total Assets                                                                                                                               
 ​                                                                                                                                          
 Liabilities and stockholder’s equity                                                                                                       
 Current liabilities:                                                                                                                       | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​            
 December 31, 
 2024         
 ​            
 ​            |    ​ 
    — 
    ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​    
 2023 
 ​    
 ​    |    ​ 
    — 
    ​ |
|:-------------------------------------------------------------------------------------------------------------------------------------------|:--|:-------------|-----:|:--|:-----|-----:|
| Accrued expenses                                                                                                                           | ​ | $            |  805 | ​ | $    |  400 |
| Total liabilities                                                                                                                          | ​ |              |  805 | ​ |      |  400 |
| Commitments and Contingencies (Note 4)                                                                                                     | ​ |              |      | ​ |      |      |
| ​                                                                                                                                          | ​ | ​            |    ​ | ​ | ​    |    ​ |
| Stockholder’s equity                                                                                                                       | ​